AAIC 2026 findings suggest that an Alzheimer's blood-biomarker test can help clinicians assess adults who already have new memory or thinking symptoms, including in primary care. The most useful questions are whether a specific test fits your symptoms, how its result will change the next step, and whether confirmation or referral is needed.
A blood-biomarker test measures markers in blood that can inform an Alzheimer's evaluation. In an interim Swedish study of symptomatic patients, primary-care clinicians improved their Alzheimer's diagnostic accuracy after receiving PrecivityAD2 results. The Alzheimer's Association AAIC 2026 report described 1,310 people with mild cognitive impairment or dementia, including 383 assessed in primary care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Is a blood test appropriate for my symptoms?
- How much did the AAIC study change primary-care decisions?
- What would a negative result mean?
- Does a positive result need confirmation?
- What should I know about FDA-cleared testing?
Is a blood test appropriate for my symptoms?
Ask whether your symptoms make a blood-biomarker test useful now. The AAIC study involved people already being evaluated for mild cognitive impairment or dementia, not people without symptoms seeking routine screening. You might ask: A test result is one piece of a clinical evaluation, not a substitute for discussing your symptoms, medical history, and daily changes with a clinician.
- "What question would this test help answer in my case?"
- "Do my symptoms call for a primary-care assessment, a specialist referral, or both?"
- "What other causes of memory or thinking changes are you considering?"
- "What would we do differently if the result is positive, negative, or unclear?"
How much did the AAIC study change primary-care decisions?
In the AAIC comparison, primary-care physicians' Alzheimer's diagnostic accuracy rose from 65% before they received PrecivityAD2 results to 93% afterward. Dementia specialists reached 94% in the head-to-head comparison. The Alzheimer's Association also reported that primary-care clinicians changed their working diagnosis for 30% of patients after results arrived.
That does not mean every adult with memory symptoms will receive the same diagnosis or need the same next step. It means the test gave clinicians information that often changed how they interpreted a symptomatic patient's situation. Ask, "What is your working diagnosis before the test, and what result would make you reconsider it?" That question helps make the decision process visible.
What would a negative result mean?
A negative result may be especially useful when a clinician is deciding whether Alzheimer's disease is less likely. In the AAIC study, primary-care clinicians' willingness to rule out Alzheimer's increased from 12.9% to 25% after they received results.
But a negative Alzheimer's blood-test result does not rule out other neurologic causes of cognitive symptoms. The Alzheimer's Association AAIC report specifically notes that distinction. Ask, "If this result makes Alzheimer's less likely, what will we investigate next?" A clear answer may include further evaluation, referral, or a different care plan.
Does a positive result need confirmation?
Ask whether a positive result would need confirmation before it guides major decisions. The Alzheimer's Association's clinical practice guideline says that, for symptomatic specialty-care patients, a blood test meeting specified accuracy thresholds may be used for triage; a positive triage result should be confirmed with cerebrospinal fluid testing or amyloid PET imaging.
The guideline announcement also cautions that commercially available tests vary substantially. Useful questions include: Knowing the assay's name and intended use helps you understand what the result can reasonably support.
- "Which exact assay are you considering?"
- "Is it being used for triage or as part of a broader diagnostic evaluation?"
- "Would a positive result require confirmation?"
- "What follow-up test or referral would you recommend?"
What should I know about FDA-cleared testing?
In the United States, the FDA-cleared Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test is intended for adults age 55 or older who have cognitive-decline symptoms and are being evaluated in specialized care. The FDA says clinicians should interpret it alongside other clinical information. The FDA approval notice also states that it is not a screening test or a stand-alone diagnosis.
Ask whether a proposed test is FDA-cleared, whether its intended use matches your situation, and what safeguards the clinician uses to address false positive or false negative results. The FDA warns that an incorrect result can lead either to inappropriate treatment or to delayed effective care. Bring a brief timeline of when symptoms began, examples of day-to-day changes, current medicines, and a trusted person's observations to the appointment.
You Might Also Like
- The NIA 2026 Dementia Care and Caregiving Summit Report: Questions Family Caregivers Can Ask Local Care Programs
- The $781 Billion Dementia Economic Estimate in the 2026 NIA Report: Questions Family Caregivers Can Ask Local Care Programs
- Caregiver Job and Retirement Losses in the 2026 NIA Report: Questions Family Caregivers Can Ask Local Care Programs
